APRIL 26-27, 2016

Registration is now CLOSED

The way in which cancer researchers deal with data is rapidly changing as the speed and power of biologic research has shattered previously defined limits. Computers and new technologies can now capture extremes in the complexity of biological life, making it increasingly necessary to approach data collection, storage and interpretation differently.

Collaboration is crucial for data gathering and data interpretation, and how it is done will determine how soon we can improve outcomes for cancer patients. Hope Funds has been intimately involved in some of these developments. At this Convening, participants will explore cutting-edge science with the potential to accelerate the rate of providing new treatments to people with difficult-to-treat cancers. Scientists will explore novel ways of addressing and improving translating extensive findings into usable information, a field called Big Data. Hope Funds for Cancer Research believes we are at a critical junction in cancer research that requires increased scientific collaboration, which will be a central focus at this Convening.

Of the 25 speakers confirmed, two are Nobel Laureates in Medicine or Physiology, two have received Lasker Awards, and two have won the Breakthrough Prize. In addition, the principal contributors to the drugs Herceptin, Neupogen, and Rituxan, as well as the leukemia regimen 7-plus-3, will be participating. These luminaries will contribute to the convening, by delivering talks, sitting on panel discussions, and participating in a group workshop with Google’s Kirk Vallis as a moderator. Mr. Vallis is an expert in facilitating collaboration among scientists.

Convening Agenda

The aim of the Hope Funds for Cancer Research Scientific Convening is not only to highlight recent exciting advances, but to lay the groundwork for new advances in this field by bringing the best minds in cancer research to facilitate the next golden-age of discoveries and treatments.

cancer cell signaling and transcription
cancer metabolism
cancer stem cells/tumor-initiating cells
computational biology
RNA, RNAi, mRNA and micro-RNA

Imre Bartos, Columbia University
Lewis C. Cantley, Weill Cornell Medical School
Don Cleveland, UC San Diego
Harold P. Freeman, Harold P. Freeman Institute for Patient Navigation
Antonio J. Grillo-López, Idec Pharmaceuticals retired
William C. Hahn, The Broad Institute and Dana-Farber Cancer Institute
James Holland, Mt. Sinai Medical School
Tyler Jacks, Koch Institute for Integrative Cancer Research
Joan Massagué, Sloan-Kettering Institute
Craig Mello, University of Massachusetts Medical School
Malcolm A.S. Moore, Sloan-Kettering Institute
Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center
David C. Page, Whitehead Institute at MIT
Robert G. Roeder, Rockefeller University

Joan A. Steitz, Yale University
Sohail Tavazoie, Rockefeller University
Craig Thompson, Sloan-Kettering Institute
James D. Watson, Cold Spring Harbor Laboratory
Robert A. Weinberg, Whitehead Institute at MIT

Bryan R.G. Williams, Hudson Institute of Medical Research
Monte Winslow, Stanford University
Richard Young, Whitehead Institute at MIT
currently in formation

Eugene Kennedy, Trustee, Hope Funds for Cancer Research
Adrian Hobden, Trustee, Hope Funds for Cancer Research
Malcolm A.S. Moore, Sloan-Kettering Institute
Andrew Robertson, BBDO Worldwide
Bryan R.G. Williams, Hudson Institute of Medical Research

Hope Funds for Cancer Research: Advancing Innovative Research in Understudied Cancers

The Hope Funds for Cancer Research is a non-profit organization (509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service’s code) that was formed in 2006 by individuals with experience in oncology, intellectual property law, investment banking, philanthropy, sociology, and the arts to fund to the most interesting and promising academic research addressing the most difficult-to-treat cancers. Hope Funds for Cancer Research provides fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including (but not limited to) pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS. Proceeds from all Hope Funds for Cancer Research activities, including this convening, support our research Fellows.